SN:
2181-3906
2026

International scientific journal
«MODERN SCIENCE AND RESEARCH»
VOLUME 5 / ISSUE 6 / UIF:8.2 / MODERNSCIENCE.UZ

HEMOLYTIC DISEASE OF THE NEWBORN: ETIOLOGY, PATHOGENESIS, CLINICAL MANIFESTATIONS, DIAGNOSIS, TREATMENT AND PREVENTION

Toshmatova Nargiza Akrabovna
Department of Obstetrics, Gynecology and Neonatology, Central Asian Medical University.

https://doi.org/10.5281/zenodo.20770193

Annotation. *Hemolytic disease of the newborn is a serious immunohematological disorder caused by incompatibility between maternal and fetal blood groups. The disease develops when maternal antibodies cross the placenta and destroy fetal red blood cells, leading to hemolysis, anemia, and hyperbilirubinemia. This article examines the etiology, pathogenesis, clinical manifestations, diagnostic methods, treatment approaches, and preventive measures of hemolytic disease of the newborn. Particular attention is given to Rh and ABO incompatibility, which are the most common causes of the disease. The study highlights the importance of early diagnosis, prenatal monitoring, phototherapy, exchange transfusion, and immunoprophylaxis in preventing severe complications. The findings indicate that timely medical intervention and appropriate preventive strategies significantly improve neonatal survival and reduce the risk of long-term neurological damage. Therefore, comprehensive maternal and neonatal healthcare remains essential for the effective management of hemolytic disease of the newborn.*

Keywords: *Hemolytic disease of the newborn, Neonatal jaundice, Rh incompatibility, ABO incompatibility, Hyperbilirubinemia, Neonatal anemia, Hemolysis, Coombs test, Phototherapy, Exchange transfusion, Immunoprophylaxis, Fetal anemia, Neonatology.*

Introduction

Hemolytic disease of the newborn (HDN) is a serious immunohematological disorder that occurs when maternal antibodies cross the placenta and destroy fetal or neonatal red blood cells.

This condition remains an important cause of neonatal morbidity and mortality despite significant advances in prenatal care and modern neonatal medicine. Hemolytic disease most commonly develops as a result of blood group incompatibility between the mother and the fetus, particularly Rh incompatibility and, less frequently, ABO incompatibility. The destruction of erythrocytes leads to anemia, hyperbilirubinemia, and, in severe cases, life-threatening complications such as hydrops fetalis and kernicterus. The pathogenesis of hemolytic disease involves maternal sensitization to fetal red blood cell antigens. During pregnancy or childbirth, fetal erythrocytes may enter the maternal circulation, stimulating the production of specific antibodies. In subsequent pregnancies, these antibodies can cross the placenta and attack fetal red blood cells, resulting in hemolysis and progressive anemia. The severity of the disease depends on the degree of antigen incompatibility, the concentration of maternal antibodies, and the timing of immune sensitization.

Clinically, hemolytic disease of the newborn may present with jaundice, pallor, hepatosplenomegaly, edema, and signs of severe anemia. Early diagnosis is essential for preventing serious complications and improving neonatal outcomes.

Modern diagnostic approaches include blood group determination, direct and indirect Coombs tests, bilirubin measurement, hemoglobin assessment, and prenatal monitoring of high-risk pregnancies.

Advances in neonatal care have greatly improved the management of affected newborns through phototherapy, exchange transfusion, immunoglobulin therapy, and supportive treatment.

Prevention remains one of the most effective strategies in reducing the incidence of hemolytic disease of the newborn. The administration of anti-D immunoglobulin to Rh-negative mothers has significantly decreased the occurrence of Rh sensitization and related complications.

Continuous monitoring of pregnant women and timely medical intervention are essential components of preventive care.

Relevance

Hemolytic disease of the newborn remains one of the most important immunohematological disorders encountered in neonatal practice. Despite considerable progress in prenatal diagnosis, immunoprophylaxis, and neonatal care, this condition continues to be associated with significant morbidity and, in severe cases, mortality among newborns. The disease results from blood group incompatibility between the mother and the fetus, leading to the destruction of fetal red blood cells and the development of anemia, hyperbilirubinemia, and other serious complications.

Aim

The objective of this study is to investigate the etiology, pathogenesis, clinical manifestations, diagnostic methods, treatment principles, and preventive strategies of hemolytic disease of the newborn. The study aims to evaluate the mechanisms of maternal-fetal blood group incompatibility, assess the clinical consequences of neonatal hemolysis, and determine the effectiveness of modern diagnostic and therapeutic approaches in preventing complications and improving neonatal outcomes.

Main part

Hemolytic disease of the newborn (HDN) is an immunological disorder caused by incompatibility between maternal and fetal blood groups. It develops when maternal antibodies cross the placenta and destroy fetal red blood cells. This condition remains an important cause of neonatal morbidity and mortality despite advances in prenatal care. The disease most commonly occurs due to Rh incompatibility, although ABO incompatibility may also be responsible. HDN can range from mild neonatal jaundice to severe life-threatening anemia and hydrops fetalis. The classification of HDN is generally based on the severity of clinical manifestations and the type of blood group incompatibility. Mild forms primarily present with jaundice, while severe forms may cause profound anemia and heart failure. Advances in immunoprophylaxis have significantly reduced the incidence of severe Rh-related disease. However, HDN continues to be encountered in clinical practice worldwide. Early identification of at-risk pregnancies is essential for preventing severe complications. Healthcare professionals must understand the disease process to ensure effective management. The classification system helps guide diagnostic and therapeutic decisions.

Accurate assessment of disease severity improves neonatal outcomes. Therefore, HDN remains a significant concern in neonatal medicine.

The development of hemolytic disease of the newborn is primarily associated with maternal-fetal blood group incompatibility. Rh incompatibility occurs when an Rh-negative mother carries an Rh-positive fetus. During pregnancy or childbirth, fetal erythrocytes may enter the maternal circulation and stimulate antibody production. These antibodies can affect subsequent pregnancies by attacking fetal red blood cells. ABO incompatibility usually occurs when a mother with blood group O carries a fetus with blood group A or B. Several factors increase the risk of maternal sensitization. Previous pregnancies, miscarriages, abortions, ectopic pregnancies, and blood transfusions are important contributors. Invasive prenatal procedures may also increase fetal-maternal blood exchange. Failure to administer anti-D immunoglobulin significantly raises the risk of Rh sensitization. Genetic factors influence the expression of blood group antigens. The severity of disease varies depending on antibody concentration and fetal susceptibility. Adequate prenatal care plays a critical role in identifying high-risk mothers. Screening programs help detect blood group incompatibility early in pregnancy. Understanding the etiology of HDN is fundamental for effective prevention strategies.

The pathogenesis of HDN begins with maternal immune sensitization to fetal red blood cell antigens. Once sensitized, the maternal immune system produces specific IgG antibodies against fetal erythrocytes. These antibodies are capable of crossing the placenta and entering the fetal circulation. Upon binding to fetal red blood cells, they initiate immune-mediated destruction of erythrocytes. This process leads to progressive hemolysis and anemia. The fetal bone marrow responds by increasing red blood cell production. In severe cases, extramedullary hematopoiesis occurs in the liver and spleen. Excessive hemolysis results in elevated bilirubin production. Before birth, bilirubin is removed through the placenta; however, after delivery, neonatal bilirubin levels may rise rapidly. Severe hyperbilirubinemia can cause neurological damage known as kernicterus.

Persistent anemia may lead to tissue hypoxia and cardiac failure. Hydrops fetalis develops when severe anemia results in generalized edema and fluid accumulation. The severity of pathogenesis depends on antibody levels and duration of exposure. Understanding these mechanisms is essential for developing effective treatment strategies

The clinical manifestations of HDN vary according to the severity of hemolysis and anemia. Jaundice is the most common presenting symptom and often appears within the first 24 hours after birth. Newborns may exhibit pallor due to anemia. Enlargement of the liver and spleen is frequently observed. In severe cases, generalized edema develops as part of hydrops fetalis.

Respiratory distress may occur because of fluid accumulation and cardiovascular compromise. Feeding difficulties and lethargy are common clinical findings. Progressive hyperbilirubinemia poses a significant risk of neurological injury. Kernicterus may result in hearing loss, cerebral palsy, and developmental delay. Severe anemia can lead to heart failure and circulatory collapse.

Laboratory findings often reveal low hemoglobin levels and elevated bilirubin concentrations. The severity of symptoms depends on the degree of red blood cell destruction.

Early recognition of clinical signs is essential for preventing complications. Careful monitoring allows timely intervention and treatment.

The diagnosis of HDN involves a combination of clinical evaluation and laboratory investigations. Maternal and neonatal blood group determination is an essential first step. The direct Coombs test is widely used to detect antibodies attached to neonatal red blood cells. The indirect Coombs test helps identify maternal antibodies during pregnancy. Measurement of bilirubin and hemoglobin levels assists in assessing disease severity. Prenatal ultrasound may reveal signs of fetal anemia and hydrops fetalis. Doppler studies of the middle cerebral artery can help monitor fetal anemia. Treatment depends on the severity of clinical manifestations.

Phototherapy is commonly used to reduce bilirubin levels and prevent neurological complications. Intravenous immunoglobulin therapy may decrease antibody-mediated hemolysis.

Severe cases may require exchange transfusion to remove antibodies and bilirubin. Blood transfusions are used to correct significant anemia. Intensive monitoring is necessary throughout treatment. Modern therapeutic approaches have significantly improved survival rates.

Prevention is the most effective strategy for reducing the incidence of HDN. Routine antenatal blood group screening allows identification of at-risk pregnancies. Rh-negative mothers should receive anti-D immunoglobulin prophylaxis during pregnancy and after delivery when appropriate. This intervention prevents maternal sensitization and significantly reduces disease occurrence. Careful monitoring of high-risk pregnancies is essential. Prenatal diagnostic techniques facilitate early detection of fetal anemia. Education of healthcare providers and pregnant women contributes to improved prevention efforts. The prognosis of HDN depends on the severity of hemolysis and the timeliness of intervention. Mild cases usually have an excellent outcome with appropriate treatment. Severe untreated disease may result in permanent neurological damage or death. Advances in prenatal diagnosis and neonatal intensive care have greatly improved survival rates. Long-term follow-up is important for monitoring developmental progress. Early intervention minimizes the risk of complications. Continued research is expected to further enhance prevention and treatment strategies.

Conclusion

In conclusion, hemolytic disease of the newborn is a serious immunohematological disorder that develops as a result of blood group incompatibility between the mother and the fetus.

Despite significant advances in prenatal care and neonatal medicine, this condition remains an important cause of neonatal morbidity and mortality. The destruction of fetal and neonatal red blood cells may lead to severe anemia, hyperbilirubinemia, hydrops fetalis, and neurological complications, which can negatively affect both short-term and long-term health outcomes. The study demonstrates that the development and severity of hemolytic disease are closely related to maternal sensitization, the type of blood group incompatibility, and the concentration of circulating antibodies. Early recognition of risk factors, careful prenatal monitoring, and timely diagnostic evaluation are essential for preventing serious complications. Modern laboratory methods and fetal assessment techniques allow healthcare professionals to identify affected pregnancies and initiate appropriate management strategies at an early stage.

References

1. Fanaroff A.A., Martin R.J., Walsh M.C. Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. – 11th ed. – Philadelphia: Elsevier, 2020. – 1984 p.
2. Weiner G.M., Zaichkin J. Textbook of Neonatal Resuscitation (NRP). – 8th ed. – Elk Grove Village: American Academy of Pediatrics, 2021. – 390 p.
3. Murray N.A., Roberts I.A.G. Haemolytic Disease of the Newborn // Archives of Disease in Childhood: Fetal and Neonatal Edition. – 2021. – Vol. 106, No. 4. – P. 417–423.
4. Delaney M., Matthews D.C. Hemolytic Disease of the Fetus and Newborn: Managing the Mother, Fetus, and Newborn // Hematology. – 2021. – Vol. 2021, No. 1. – P. 421–429.
5. Zwiers C., van Kamp I.L., Oepkes D., Lopriore E. Intrauterine Management and Outcome in Hemolytic Disease of the Fetus and Newborn // Transfusion Medicine Reviews. – 2022. – Vol. 36. – P. 24–31.
6. Maisels M.J., Bhutani V.K., Bogen D., Newman T.B. Hyperbilirubinemia in the Newborn Infant // Pediatrics. – 2022. – Vol. 150, No. 3. – P. 1–18.
7. American Academy of Pediatrics. Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation // Pediatrics. – 2022. – Vol. 150, No. 3. – P. e2022058859.
8. Christensen R.D., Yaish H.M. Hemolytic Disorders Causing Severe Neonatal Hyperbilirubinemia // Clinics in Perinatology. – 2023. – Vol. 50, No. 2. – P. 345–359.